NCT07125391View on ClinicalTrials.gov

Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

August 30, 2026

Study Completion Date

June 30, 2027

Conditions
Ovarian Cancer
Interventions
DRUG

Cohort A

received propranolol hydrochloride (20mg, BID, QD), paclitaxel/paclitaxel liposome (135-175mg/m2, d1, Q3W), carboplatin (AUC=4-5, d1, Q3W) for 3-4 cycles of neoadjuvant therapy. Subsequently, interval debulking surgery (IDS) was performed. Propranolol hydrochloride was taken one week before neoadjuvant therapy

Trial Locations (1)

230001

RECRUITING

Anhui Cancer Hospitail, Hefei

All Listed Sponsors
lead

Bai-Rong Xia

OTHER

NCT07125391 - Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer | Biotech Hunter | Biotech Hunter